



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1999PLC086581

Date: 27/04/2024

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Sub.: Compliance Certificate as per Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2024.

Please find enclosed Compliance Certificate as per Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2024.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You,

Yours truly,

FOR NORRIS MEDICINES LIMITED

VIMAL Digitally signed
by VIMAL D SHAH
D SHAH Date: 2024.04.27
12:33:25 +05'30'

VIMAL DHIRENDRA SHAH
DIRECTOR
DIN: 01506655

**CERTIFICATE UNDER REGULATION 40(9) OF THE (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

FOR THE YEAR ENDED MARCH 31, 2024


We have examined all Share Transfer Deeds, Memorandum of Transfers, Registers, files and other documents relating to **NORRIS MEDICINES LIMITED** maintained by **Purva Shareregistry (India) Pvt. Ltd. (RTA)** pertaining to transfer of equity shares of the company for the period from **April 01, 2023 to March 31, 2024** for the purpose of issuing a Certificate as per Regulation 40(9) of the **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015** and hereby certify that:

- A) During the year ended **March 31, 2024**, the Company did not receive any request for transfer of shares, hence it was not required to deliver any share certificate during the period from **April 01, 2022 to March 31, 2024**.
- B) The Company has delivered during the year ended **March 31, 2024** share certificates relating to requests received for change of name for **150 (One Hundred and Fifty)** shares from 3 (three) shareholders during the period from April 01, 2023 to March 31, 2024 within 30 days from the respective date of lodgment. Further as per the records provided to us there were no requests relating to renewal/Sub-division (split), consolidation, duplication of shares or endorsement of calls/allotment monies received and there were **1770 (One Thousand Seven Hundred and Seventy)** Shares requests relating to duplication of shares, **270 (Two Hundred and Seventy)** Shares for relating to name deletion, **2470 (Two Thousand Four Hundred and Seventy)** Shares for relating to Objections of shares and **1830 (One Thousand Eight Hundred and Thirty Only)** shares relating to transmission of shares during the period from April 01, 2023 to March 31, 2024.

Place: Mumbai
Date: 26th April, 2024
ICSI UDIN: F002827F000246873
Peer Review No: 2507/2022



HSPN& Associates LLP
Company Secretaries


Hemant Shetye
Designated Partner
COP No: 1483
FCS: 2827